|
US2014121159A1
|
|
Terminally-functionalized conjugates and uses thereof
|
|
WO2012050822A1
|
|
Uses of macrophage mannose receptor to screen compounds and uses of these compounds
|
|
EP2598522A2
|
|
Recombinant lectins, binding-site modified lectins and uses thereof
|
|
WO2012015692A2
|
|
Recombinantly expressed insulin polypeptides and uses thereof
|
|
CA2805743A1
|
|
Drug-ligand conjugates, synthesis thereof, and intermediates thereto
|
|
SG173117A1
|
|
Crystalline insulin-conjugates
|
|
CA2750262A1
|
|
Conjugate based systems for controlled drug delivery
|
|
CA2750245A1
|
|
Polynucleotide aptamer-based cross-linked materials and uses thereof
|
|
UA104014C2
|
|
Conjugate for sustained release formulations of insulin
|
|
WO2010107520A1
|
|
Soluble non-depot insulin conjugates and uses thereof
|
|
AU2010208381A1
|
|
Exogenously triggered controlled release materials and uses thereof
|
|
WO2010088261A1
|
|
Binding-site modified lectins and uses thereof
|
|
AU2010226243A1
|
|
Terminally-functionalized conjugates and uses thereof
|
|
AU2010208305A1
|
|
Synthetic conjugates and uses thereof
|
|
WO2007047922A2
|
|
Polymer-drug conjugates
|
